An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis.

Autor: Ošep AB; General Hospital Celje, Department of Neurology, Oblakova Ulica 5, 3000 Celje, Slovenia., Brecl E; General Hospital Celje, Department of Neurology, Oblakova Ulica 5, 3000 Celje, Slovenia. Electronic address: breclova.eva@gmail.com., Škerget M; University Medical Centre Ljubljana, Department of Haematology, Zaloška Cesta 2, 1000 Ljubljana, Slovenia; University of Ljubljana, Faculty of Medicine, Vrazov Trg 2, 1000 Ljubljana, Slovenia., Savšek L; General Hospital Celje, Department of Neurology, Oblakova Ulica 5, 3000 Celje, Slovenia; University of Ljubljana, Faculty of Medicine, Vrazov Trg 2, 1000 Ljubljana, Slovenia.
Jazyk: angličtina
Zdroj: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2023 May; Vol. 228, pp. 107675. Date of Electronic Publication: 2023 Mar 14.
DOI: 10.1016/j.clineuro.2023.107675
Abstrakt: Alemtuzumab is a humanized monoclonal antibody indicated for treatment of highly active relapsing-remitting multiple sclerosis (HA-RRMS). It binds to CD52 antigen and produces a rapid and prolonged lymphocyte depletion followed by a different pattern of T and B cell repopulation. Among others, its adverse events are autoimmune diseases.In this article, we present a patient with HA-RRMS, who was subsequently treated with alemtuzumab and afterwards developed hemophagocytic lymphohistiocytosis (HLH). Albeit rarely, HLH can be triggered by alemtuzumab treatment.HLH can favourably respond to prompt immunosuppressant therapy.Multidisciplinary approach by a team consisting of a neurology, hematology and rheumatology specialist is needed to treat this potentially lethal condition.
Competing Interests: Conflict of interest Authors have no relevant conflict of interest, financial or otherwise.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: